Biostage (OTCMKTS:BSTG) vs. Acutus Medical (NASDAQ:AFIB) Head-To-Head Review

Biostage (OTCMKTS:BSTG) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

56.9% of Acutus Medical shares are owned by institutional investors. 15.3% of Biostage shares are owned by insiders. Comparatively, 5.2% of Acutus Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Biostage and Acutus Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67
Acutus Medical	$7.16 million	0.00	-$81.66 million	N/A	N/A

Biostage has higher earnings, but lower revenue than Acutus Medical.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Biostage and Acutus Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostage	0	0	1	0	3.00
Acutus Medical	0	0	0	0	0.00

Profitability

This table compares Biostage and Acutus Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostage	N/A	N/A	-174.43%
Acutus Medical	-272.74%	-311.64%	-11.57%

Volatility and Risk

Biostage has a beta of -1.02, suggesting that its share price is 202% less volatile than the S&P 500. Comparatively, Acutus Medical has a beta of -0.67, suggesting that its share price is 167% less volatile than the S&P 500.

Summary

Biostage beats Acutus Medical on 6 of the 10 factors compared between the two stocks.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.